Texas Yale Capital Corp’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.2M Buy
4,419
+75
+2% +$33.2K 0.05% 206
2026
Q1
$1.94M Buy
4,344
+75
+2% +$35K 0.06% 203
2025
Q4
$1.94M Buy
4,269
+181
+4% +$78K 0.06% 209
2025
Q3
$1.6M Buy
4,088
+120
+3% +$50.2K 0.05% 220
2025
Q2
$1.77M Sell
3,968
-125
-3% -$57.6K 0.06% 199
2025
Q1
$1.98M Hold
4,093
0.08% 186
2024
Q4
$1.65M Sell
4,093
-115
-3% -$53.3K 0.07% 202
2024
Q3
$1.96M Hold
4,208
0.09% 193
2024
Q2
$1.97M Sell
4,208
-10
-0.2% -$4.34K 0.09% 176
2024
Q1
$1.76M Buy
4,218
+439
+12% +$186K 0.08% 193
2023
Q4
$1.54M Buy
+3,779
New +$1.4M 0.07% 201

Other funds holding VRTX

Texas Yale Capital Corp's VRTX Position: Q2 2026 in Review

Texas Yale Capital Corp increased its Vertex Pharmaceuticals (VRTX) stake by 1.7% in Q2 2026, buying an estimated $33.2K and bringing the position to 4,419 shares worth $2.2M. The position accounts for 0.05% of the portfolio, ranked #206.

Texas Yale Capital Corp first reported a position in VRTX in Q4 2023 and has held it in 11 quarters since. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Texas Yale Capital Corp held 4,419 shares of Vertex Pharmaceuticals worth $2.2M as of Q2 2026.
  • Texas Yale Capital Corp bought 75 Vertex Pharmaceuticals shares in Q2 2026, an estimated $33.2K.
  • Vertex Pharmaceuticals made up 0.05% of Texas Yale Capital Corp's portfolio in Q2 2026, its #206 holding.
  • Texas Yale Capital Corp first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Texas Yale Capital Corp's 13F filing for Q2 2026, filed 12 Aug 2026.